Caxton Associates LLP Invests $389,000 in Avanos Medical, Inc. $AVNS

Key Points

• Caxton Associates LLP has acquired 27,116 shares of Avanos Medical, valued at approximately $389,000, indicating a growing interest from institutional investors.
• Avanos Medical's quarterly earnings missed estimates with an EPS of $0.17, lower than the expected $0.18, while revenue for the quarter was $175 million, surpassing expectations.
• Stock analysts have issued mixed ratings for Avanos Medical, with Wall Street Zen downgrading the stock from "strong-buy" to "buy," and Zacks Research upgrading it to a "hold" rating.

Caxton Associates LLP purchased a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 27,116 shares of the company's stock, valued at approximately $389,000. Caxton Associates LLP owned about 0.06% of Avanos Medical at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. State of Wyoming lifted its holdings in shares of Avanos Medical by 132.0% during the fourth quarter. State of Wyoming now owns 5,137 shares of the company's stock worth $82,000 after buying an additional 2,923 shares in the last quarter. Heritage Family Offices LLP acquired a new stake in shares of Avanos Medical during the first quarter worth $146,000. EntryPoint Capital LLC acquired a new stake in shares of Avanos Medical during the first quarter worth $181,000. ProShare Advisors LLC lifted its holdings in shares of Avanos Medical by 44.4% during the fourth quarter. ProShare Advisors LLC now owns 13,693 shares of the company's stock worth $218,000 after buying an additional 4,210 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Avanos Medical during the fourth quarter worth $233,000. Institutional investors and hedge funds own 95.17% of the company's stock.

Insider Transactions at Avanos Medical

In other Avanos Medical news, Director Gary Blackford bought 40,000 shares of the firm's stock in a transaction on Wednesday, August 13th. The shares were purchased at an average price of $10.99 per share, for a total transaction of $439,600.00. Following the completion of the transaction, the director directly owned 40,000 shares in the company, valued at approximately $439,600. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.64% of the stock is currently owned by corporate insiders.

Avanos Medical Price Performance

Avanos Medical stock traded up $0.42 during midday trading on Thursday, reaching $12.28. The company's stock had a trading volume of 609,901 shares, compared to its average volume of 514,608. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.36. The company has a current ratio of 2.64, a quick ratio of 1.58 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average price of $11.62 and a 200-day moving average price of $12.51. The stock has a market cap of $569.82 million, a PE ratio of -1.22 and a beta of 1.12.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. The business had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. During the same quarter in the prior year, the firm earned $0.34 EPS. Avanos Medical has set its FY 2025 guidance at 0.750-0.950 EPS. On average, sell-side analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Avanos Medical from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Zacks Research raised Avanos Medical to a "hold" rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Avanos Medical has a consensus rating of "Hold".

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.